Dr. Esin Kosal has over 20 years of global regulatory experience with focus on the development, registration and successful launches of new chemical entities including rare disease products. With her in-depth knowledge in regulatory and drug development, she has contributed to the ever-evolving regulatory landscape for establishing global development programs.
Most recently at Mitsubishi Tanabe Pharmaceuticals, Dr. Kosal led establishing the regulatory affairs strategies for development products. Her previous positions included serving as Vice President, Global Regulatory Affairs at Axovant Pharmaceuticals, where she oversaw the global regulatory affairs activities for Phase-2 and Phase-3 studies and NDA preparation. Additionally, as Global Regulatory Affairs Head at SKLSI Pharmaceuticals, she created and implemented global strategies during the development of multiple products including orphan drug application.
She also held several leadership positions in global regulatory affairs at BMS, Pfizer, and Forest Labs.
Dr. Kosal has a Ph.D. in molecular thermodynamics from the University of Pittsburgh. She studied Medicinal Chemistry as a Post-Doc researcher at Northeastern University. In addition, she earned two M.S. degrees in Chemical Engineering and Analytical Chemistry.